Santhera Pharmaceuticals Holding AG /
Santhera Announces First Patient Dosing with Omigapil in Congenital Muscular
Dystrophy (CMD) and Full Patient Recruitment of CALLISTO Study
. Processed and transmitted by NASDAQ OMX Corporate Solutions.
The issuer is solely responsible for the content of this ...
↧